Sign in

CANF on NYSE

Can Fite Biopharma

Logo: canfite.com4

Can Fite Biopharma is a Biopharmaceutical company based in Petah Tikva, founded in 1994.1 Its shares trade on NYSE under the symbol CANF.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$405.0KRevenue, fiscal 20255
-$9.8MNet income, fiscal 20255
1994Founded1

Compare with MEDICINOVA INC, Selecta Biosciences (United States) or America Great Health, or pick any stock.

  • TickerCANF on NYSE1
  • Industrybiopharmaceutical1
  • Headquartersפתח תקווה1
  • Founded inIsrael1
  • Websitewww.canfite.com
  • Legal formlimited company, public company1
  • Listed onNew York Stock Exchange (CANF), Tel Aviv Stock Exchange (CANF)1
  • Incorporated inIsrael6
  • Business address26 Ben Gurion Street, Ramat Gan, L3 52573466
  • Filer categoryNon-accelerated filer6
  • LEI549300ZLRH6GSBOHFZ593
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressPO BOX 7537, 4917000 Petach-Tikva, Israel3
  • Registered withIsraeli Corporations Authority (Department of Justice), 5120221533

See how the biggest companies compare on our leaderboards

Can Fite Biopharma image from its website
Image: canfite.com4

2026. In addition, we have out-licensed the following product candidates for indications that we are currently pursuing:7 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-2456.8%Operating margin5
-2426.7%Net margin5
-39.9%Revenue growth, 20255
-175.8%Return on equity5
-$9.0MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$6.7M

Out of $405.0K in revenue.5 The company lost money this year.

Financial statements

Revenue8910115$405.0K in 2025−89% since 2018
0$1.0M$2.0M$3.0M$4.0M2018: $3.8M$3.8M20182019: $2.0M$2.0M2019−47%2020: $763.0K$763.0K2020−62%2021: $853.0K$853.0K2021+12%2022: $810.0K$810.0K2022−5%2023: $743.0K$743.0K2023−8%2024: $674.0K$674.0K2024−9%2025: $405.0K$405.0K2025−40%
Operating income891012115-$9.9M in 2025+84% since 2018
-$15.0M-$10.0M-$5.0M02018: -$5.4M-$5.4M20182019: -$12.0M-$12.0M2019+122%2020: -$14.1M-$14.1M2020+18%2021: -$12.8M-$12.8M2021−9%2022: -$10.1M-$10.1M2022−21%2023: -$8.2M-$8.2M2023−19%2024: -$8.1M-$8.1M2024−1%2025: -$9.9M-$9.9M2025+22%
Net income891012115-$9.8M in 2025+50% since 2018
-$15.0M-$10.0M-$5.0M02018: -$6.6M-$6.6M20182019: -$12.6M-$12.6M2019+92%2020: -$14.4M-$14.4M2020+14%2021: -$12.6M-$12.6M2021−13%2022: -$10.2M-$10.2M2022−19%2023: -$7.6M-$7.6M2023−25%2024: -$7.9M-$7.9M2024+3%2025: -$9.8M-$9.8M2025+25%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Revenues$405.0K$674.0K$743.0K
Research and development expenses-$6.7M-$5.8M-$6.0M
General and administrative expenses-$3.7M-$3.0M-$3.0M
Total operating expenses-$10.4M-$8.8M-$8.9M
Operating loss-$9.9M-$8.1M-$8.2M
Total financial income, net$122.0K$250.0K$561.0K
Loss before taxes on income, Amount-$9.8M-$7.9M-$7.6M
Net loss-$9.8M-$7.9M-$7.6M
Basic net loss per share (in Dollars per share)-$5.97-$10.86-$17.92
Diluted net loss per share (in Dollars per share)-$5.97-$10.86-$17.92
Weighted average number of ordinary shares used in computing basic net loss per share1.6M shares725.3K shares426.1K shares
Weighted average number of ordinary shares used in computing diluted net loss per share1.6M shares725.3K shares426.1K shares

Compare Can Fite Biopharma with another company

Corporate structure

Can Fite Biopharma sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Can Fite Biopharma

  • Can Fite Biopharma Petach-Tikva, Israel

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Can Fite Biopharma reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$17.0K5 Dec 31, 2025$79.0K5 Dec 31, 2024−78.5%
Accumulated depreciation$12.0K5 Dec 31, 2025$52.0K5 Dec 31, 2024−76.9%
Property and equipment, net$5.0K5 Dec 31, 2025$27.0K5 Dec 31, 2024−81.5%
Operating-lease assets (leased space)$69.0K5 Dec 31, 2025$111.0K5 Dec 31, 2024−37.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$5.5M5 Dec 31, 2025$4.8M5 Dec 31, 2024+14.6%
Marketable securities, current$1.0K5 Dec 31, 2025$5.0K5 Dec 31, 2024−80.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Patents, net$250.0K5 Sep 24, 2024

Leadership

Who has led Can Fite Biopharma, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Motti Farbstein2026–now

Chief financial officer

  1. Motti Farbstein2026–now

Chief operating officer

  1. Motti Farbstein2026–now
1995200020052010201520202025
Board members and other officers (7)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorIlan Cohn named Dec 30, 202121
  • DirectorYaacov Goldman named Dec 30, 202121
  • DirectorYossi Bornstein named Dec 30, 202121

Timeline

  1. Mar 18, 2026New chief executive Motti Farbstein becomes CEO14
  2. 1994Founded Founded in Israel1

Calendar

Drug trials and FDA: coming up

  1. Aug 31, 2027Phase 2 trial readout expected Phase 2 trial of Piclidenoson in Lowe Syndrome: primary completion expected Aug 31, 2027 (ClinicalTrials.gov NCT07410455).22

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

291 filings to the SEC since October 2021: 5 annual reports, 9 insider forms, 8 large holders, 2 private raises, 267 other. The latest 20:

  1. Oct 9, 2026EFFECT EDGAR
  2. Oct 9, 2026EFFECT EDGAR
  3. Oct 9, 2026424B3 PROSPECTUS EDGAR
  4. Sep 25, 2026F-3 REGISTRATION STATEMENT EDGAR
  5. Sep 25, 2026F-3/A AMENDMENT NO. 1 TO FORM F-3 EDGAR
  6. Sep 11, 2026EFFECT EDGAR
  7. Sep 11, 2026EFFECT EDGAR
  8. Sep 10, 2026D EDGAR
  9. Sep 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  10. Sep 8, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 11 TO FORM F-1 EDGAR
  11. Sep 8, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 11 TO FORM F-1 EDGAR
  12. Sep 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  13. Sep 3, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  14. Sep 2, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  15. Sep 2, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  16. Aug 28, 2026F-3 REGISTRATION STATEMENT EDGAR
  17. Aug 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  18. Aug 12, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  19. Aug 3, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  20. Jul 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR

The 291 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$18.3M 2021–2026
Money received by yearMoney received by year, 2021–2026: $18.3M in all. Private raises (Form D) $18.3M.$0$2.5M$5M$7.5M$10M2021 · Private raises (Form D): $10.0M2021202320252026 · Private raises (Form D): $8.3M2026
Figures by year
YearPrivate raises (Form D)Total
2026$8.3M$8.3M
2021$10.0M$10.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Sep 2, 2026Raised $8.3 million in a private offering of equity28 Form D: 1 investor so far Form D
  2. Dec 20, 2021Raised $10 million in a private offering of securities21 Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Citadel Advisors LLC32,533$96.6K0.0%−1,617
Rhumbline Advisers17,433$51.8K0.0%−3,475
Fifth Third Bancorp150$4460.0%No change
Wells Fargo & Company/mn59$1750.0%−66
Activest Wealth Management10$300.0%No change
TD Waterhouse Canada Inc.1$40.0%No change
Morgan Stanley1$30.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Can Fite Biopharma is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCan-Fite BioPharma Ltd.2
  • CIK0001536196
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company7
  • Incorporated inIsrael7
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address26 Ben Gurion Street, Ramat Gan, L3 52573462
  • Phone972 392411142
  • Shares outstanding2,618,425 shares as of Dec 31, 20257
  • AuditorKOST FORER GABBAY& KASIERER, Tel-Aviv, Israel PCAOB ID 1281; no auditor attestation of internal control over financial reporting7
  • On EDGAR sinceDec 1, 20112
  • Filings863 in all: 6-K (542), EFFECT (44), 424B3 (29), CORRESP (29), POS AM (26), UPLOAD (23), SC 13G/A (19), 424B5 (15)2
    All 40 form types

    D (15), SC 13G (15), 20-F (13), F-3 (12), SC 13D/A (12), F-1 (11), F-1/A (11), 3 (8), DRS/A (4), DRSLTR (3), S-8 (3), 4 (2), 424B4 (2), 6-K/A (2), CT ORDER (2), DRS (2), F-3/A (2), SC 13D (2), SCHEDULE 13G/A (2), 20-F/A (1), 20FR12G (1), 20FR12G/A (1), 3/A (1), 424B7 (1), 5 (1), 8-A12B (1), AW (1), CERTNYS (1), F-6 (1), F-6 POS (1), F-6EF (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (20-F) Mar 26, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing 2 Ordinary Shares, no par valueCANFNYSE

From the cover page of the 20-F filed Mar 26, 2026 (Section 12(b) of the Exchange Act).7

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28